Humanigen

Humanigen Equity

Delisted

The The Equity of Humanigen (HGENQ) as of Oct 3, 2026 is -46.77 M USD. In the previous year, The Equity was -23.69 M USD — a change of 97.43% (lower).

Equity

-46.77 MUSD

YoY

97.43%

Last updated:

In 2026, Humanigen's equity was -46.77 M USD, a 97.43% increase from the -23.69 M USD equity in the previous year.

The Humanigen Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
5.73 M USD
Jan 1, 2016
-4.38 M USD
Jan 1, 2017
-24.34 M USD
Jan 1, 2018
-8.11 M USD
Jan 1, 2019
-14.32 M USD
Jan 1, 2020
45.55 M USD
Jan 1, 2021
-23.69 M USD
Jan 1, 2022
-46.77 M USD
The Humanigen Equity history
YEAREquityYoY
-46.77 MUSD+97.43%
-23.69 MUSD-152.01%
45.55 MUSD-418.09%
-14.32 MUSD+76.57%
-8.11 MUSD-66.68%
-24.34 MUSD+455.71%
-4.38 MUSD-176.44%
5.73 MUSD-76.72%
24.61 MUSD—
Access this data via the Eulerpool API

Humanigen Stock analysis

What does Humanigen do? Humanigen Inc is a pharmaceutical company specializing in the discovery, development, and marketing of drugs, therapies, and solutions in the field of medical research. The company was originally founded in 2000 and is headquartered in Burlingame, California. One major focus of Humanigen Inc is the treatment of severe and life-threatening diseases such as cancer or HIV/AIDS that have not been sufficiently addressed by other medications. The company has developed a range of special technologies that enable it to develop innovative and effective therapies and drugs. An important aspect of Humanigen Inc's business model is collaboration with other companies, institutions, and research facilities worldwide. Through partnerships and cooperation, the company is able to cover the entire spectrum of research and development, allowing it to develop treatment options even faster and more effectively. Humanigen Inc has several different divisions and products designed for various applications. An important subsidiary of the company is the Humanigen Center for HIV Cure Research, which specifically focuses on combating HIV. There, the company works closely with scientists, researchers, and partners to develop new and innovative treatment options. Another important product of Humanigen Inc is the drug Lenzilumab. Lenzilumab is an antibody used to treat severe and life-threatening diseases such as cancer and COVID-19. Lenzilumab has shown great promise in clinical trials and could be the key to developing new and effective treatment options. In addition, Humanigen Inc has filed a variety of patents that enable it to develop new and innovative technologies in medical research. Many of these technologies are also licensed by other companies and research institutions, promoting the growth and expansion of Humanigen Inc. In recent years, the company has also placed a major focus on the field of digital technology. By utilizing big data, artificial intelligence, and other digital technologies, Humanigen Inc is able to develop new therapy options even faster and more effectively, catering specifically to the needs of patients and doctors. Overall, Humanigen Inc is an innovative and rapidly growing company focused on the development of new and effective treatment options for serious diseases. Through collaboration with other companies and institutions, the development of new technologies, and a targeted focus on the needs of patients and doctors, the company is able to respond even faster and more effectively to challenges in the field of medical research. Humanigen is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Humanigen's Equity

Humanigen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Humanigen's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Humanigen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Humanigen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Humanigen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Humanigen stock

The Equity of Humanigen is -46.77 M USD in 2026.

The Equity of Humanigen changed from -23.69 M USD to -46.77 M USD, representing a 97.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Humanigen since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Humanigen historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Humanigen

All Key Metrics — Humanigen